The role of the ERN EpiCARE Research Council is to support research conducted by EpiCARE members, with an aim to improve the quality and quantity of research within the network.
Specific goals include:
The EpiCARE Research Council includes EpiCARE’s Coordinator, 4 members of the EpiCARE Steering comittee, the ECET Chair, the Registry representative, the ePAG representatives, a representative of a current joint ERN/European research Initiatives (eg EJP RD, Human Brain Project that provide ressources to the network), the EpiCARE Research projects manager, the EpiCARE data manager and an ILAE representative.
The chair of EpiCARE’s Research Council is Helen Cross, deputy chair is Kees Braun. Members are Alexis Arzimanoglou, Sandor Beniczky, Ingmar Blümcke, Philippe Ryvlin, Renzo Guerrini, Rainer Surges, Eugen Trinka, Lieven Lagae, Rima Nabbout and Emilio Perucca.
An EpiCARE project will be defined as a project that is led by a number of EpiCARE members (at least 2) or from a single centre where data for a study is gathered from other EpiCARE HCP.
The project must be proposed to the research council prior to any funding application, and have undergone a quality check/peer review.
In order for ERN EpiCARE support to be given to a project, a project should be reviewed by the council. On submission, a reviewer will be nominated from the network and advice provided within 2 weeks. A letter will be provided by the Council Chair
Transformational Science Grant Awards are the largest grants awarded by DSF. Transformational Science Grants are intended for established, experienced, independent investigators affiliated with a research or academic institution whose proposed projects investigate hypotheses directly related to Dravet syndrome. Transformational Science Grants should have substantial preliminary data to support the stated hypothesis and strong potential to significantly impact the research field or move the needle on clinical care. Proposals are scored according to NIH guidelines based on the quality of preliminary data, research design, feasibility, investigator’s qualifications, and overall impact. Grants are awarded for $500,000 over 3 years (beginning January 1 of each year). Indirect costs must be included within the $500,00 budget and are not to exceed 10% of the total award.
Investigators applying for a DSF grant should ensure their proposed project addresses the needs of the Dravet syndrome community and DSF’s mission to support research toward better treatments and a cure for Dravet syndrome. Proposals should address research areas related to the DSF’s yearly priority areas and DSF’s Roadmap to a Cure.
Eligibility: Applicants should be affiliated with a research or academic institution (excluding for-profit companies), may be US or foreign based, established in their field, and in good standing with their institution.
Deadline : One stage : Mid January 2024
Animals and animal-derived materials are widely used in biomedical research and in the production and development of health technologies. This raises serious ethical concerns, and there is growing societal pressure to move towards alternative approaches and methods. Besides major ethical concerns, there is also scientific evidence that supports moving away from animal-based approaches and finding more humanrelevant methods and strategies for both the assessment of safety and efficacy of new health technologies and for manufacturing. Animal testing requires time-consuming protocols, high costs for animal supply, and the results are not always reproducible and applicable to humans. In addition, for the development and production of health technologies (e.g., in vitro diagnostics) as well as in biomedical research in general, materials of animal origin are required (e.g., biomolecules, sera). These animal-derived products require large amounts of animals for their production. Therefore, also in this context, there is a need to foster progress towards new alternatives (e.g., synthetic matrix, recombinant proteins) to reduce the overall number of animals that are bred for these purposes.
New Approach Methodologies (NAMs) and other innovative non-animal approaches have high potential to improve the development and/or the production of health technologies, while contributing to the reduction and replacement of the use of animals. Recent improved biological knowledge, technological advances, computer simulations and innovative non-animal approaches and methods (e.g., organoids, complex 3D cell models, microphysiological systems4, in silico models, non-animal derived antibodies and other biomolecules5) provide the opportunity to move forward with safer and more effective tools for protecting human health and preventing/treating diseases that would in parallel entail an improvement of animal to human translation or better production processes, as well as help progress towards the replacement of animals used in biomedical research in general.
While the potential for using non-animal approaches for the production, development and testing of new health technologies is enormous, more evidence and high-quality data for their performance evaluation in comparison with established animal-based approaches for a specific application (such as a production process, primary pharmacology, or next-generation-risk-assessment – NGRA) and for their validation are required by the industry and regulators to implement these alternative approaches in R&D and decision
The current topic seeks to address these challenges by exploiting the latest relevant scientific advancements to develop NAMs and other non-animal approaches, which could be more readily available and more efficient than the ones involving animals, and which should improve either the development, including efficacy and safety assessment, of new health technologies for infectious/non-communicable diseases or the production processes of such technologies. The projects funded under this topic should aim to:
Deadline : One stage : Mid January 2024
Multi-modal theranostics solutions, currently dominated by radionuclide-based therapy and companion diagnostics are emerging as safe, personalised, and effective approaches for the treatment of several diseases. However, use of such therapies is limited to a few specialised centres with the need to increase clinical treatment capacities, and to widen the arsenal of theranostics, possibly including novel non-nuclear approaches, e.g., enabled by nanotechnologies. To address this challenge, project(s) funded under this topic should aim at developing new, or innovative combinations of existing, multi-modal theranostics solutions including radiopharmaceuticals and/or nonradioactive theranostics solutions. Applicants should clearly identify a disease(s) of unmet public health need, (e.g., oncology, neurology and/or advanced multi-disease conditions) and explain their choice with relevant evidence where possible.
In particular, for the selected disease(s), the project(s) funded under this topic are expected to address all the following objectives:
Deadline : One stage : Mid January 2024
Healthcare research using individual patient data is often constrained due to restrictions in data access because of privacy, security, intellectual property (IP) and other concerns. Synthetic health data, i.e., data that is artificially created to mimic individual patient data, can reduce these concerns, leading to more rapid development of reliable data-driven methods including diagnostic, precision medicine, decision support and patient monitoring tools. However, while many synthetic data generation (SDG) methods are currently available, it is not always clear which method is best for which use case, and SDG methods for some types of data are still immature.
Expected impacts to be achieved by this topic
To exploit the full potential of digitalisation and data exchange in health care, this topic is expected to contribute to the following expected impacts:
Deadline model : single-stage
Planned opening date: 10 October 2023
Deadline date: 08 February 2024 17:00:00 Brussels time
Projects results are expected to contribute to the following outcomes:
For supported doctoral candidates or postdoctoral researchers
For participating organisations
Applicants submit proposals for new or existing doctoral or postdoctoral programmes with an impact on the enhancement of human resources in R&I at regional, national or international level. These programmes will be co-funded by MSCA COFUND.
Proposed programmes can cover any research disciplines (“bottom-up”), but exceptionally can also focus on specific disciplines, notably when they are based on national or regional Research and Innovation Strategies for Smart Specialisation (RIS3 strategies). In this case, the range of covered disciplines should allow reasonable flexibility for the researchers to define their topic.
COFUND takes the form of:
Doctoral programmes offer research training activities to allow doctoral candidates to develop and broaden their skills and competences. They will lead to the award of a doctoral degree in at least one EU Member State or Horizon Europe Associated Country. The training activities should be based on the EU Principles on Innovative Doctoral Training.
Postdoctoral Programmes fund individual advanced research training and career development fellowships for postdoctoral researchers. The programmes should offer training to develop key transferable skills and competences common to all fields, foster good scientific conduct such as research integrity, foster innovation and entrepreneurship and promote and (where appropriate) reward Open Science practices (open access to publications and to other research outputs including data, FAIR data management, societal engagement and citizen science, etc.).
Deadline model: single-stage
Planned opening date: 06 December 2023
Deadline date: 12 March 2024 17:00:00 Brussels time
Projects are expected to contribute to all the following expected outcomes:
This topic aims at supporting the development of new concepts for the next generation of research infrastructures of European interest, single/multi sited, distributed or virtual, that none or few countries might individually be able to implement. All fields of research can be considered.
Major upgrades of existing infrastructures may also be considered if the end result is significantly transformative and equivalent to a new infrastructure concept. The possibility to extend the scope of already existing infrastructures and/or integrate in a sustainable way existing pan-European and national capacities to address the specific RI service needs, should indeed be assessed as a first option, identifying what is missing and the necessary new developments.
Proposals for RI concept development will tackle all key questions concerning the technical and conceptual feasibility of new or upgraded fully fledged user facilities.
In this respect, proposals should address all following aspects:
Proposals should also convincingly demonstrate that the project will effectively:
Deadline model : single-stage
Planned opening date : 14 May 2024
Deadline date :04 September 2024 17:00:00 Brussels time
Project results are expected to contribute to the following outcomes:
The objective is to foster international cooperation in MSCA in Horizon Europe, through a dedicated support action to complement and ensure coordination between existing promotion channels at local level, and ensure consistency with formal R&I policy dialogues at bilateral and regional levels. Focus should be given:
Based on the outcomes of a study on the MSCA international dimension in Horizon 2020, activities to be implemented should include:
The expected duration of the action is 36 months.
The world’s largest brain research prize is Danish and is awarded by the Lundbeck Foundation. Each year, we award 10 million DKK (approx. 1,3 million€) to one or more brain researchers who have had a ground-breaking impact on brain research.
Nominations for 2023 are open
The Brain Prize recognises highly original and influential advances in any area of brain research, from basic neuroscience to applied clinical research, and winners may be of any nationality and work in any country around the globe. This broad perspective is reflected in the diverse fields of previous Brain Prize winners.
The Prize may be awarded to one or more scientists who have distinguished themselves through outstanding contributions to any field of neuroscience, from fundamental studies to research related to understanding and treatment of diseases of the brain and other parts of the nervous system.
The Global Innovation Fund (GIF) is currently inviting applications for its Grants program to support breakthrough solutions from for-profit firms, non-profit organisations, researchers, and government agencies to maximise their impact and catalyse meaningful change.
Deadline – Ongoing
The Global Innovation Fund invests in the development, rigorous testing, and scaling up of new products, services, business process, or policy reforms. Through its grants, GIF supports these breakthrough solutions from for-profit firms, non-profit organisations, researchers, and government agencies to maximise their impact and catalyse meaningful change.
If you are a non-profit and your innovation does not involve generating revenues from users or customers, a grant is likely to be most appropriate.
Stages of Funding
GIF has a staged funding approach, whereby the amount of funding available is tiered according to the level of maturity of your innovation and the activities proposed. The three tiers are:
Pilot – the innovation is at an early stage but you have a credible plan for how it can be developed and tested in a real-world setting. Funding of up to USD 230,000 is available to test core assumptions around operational, social, and financial viability.
Test and transition – the innovation has already shown promise of success at a small scale, and you have some information on your operational, social, and financial viability which you want to solidify before you scale. Funding of up to USD 2.3 million is available to support further growth and generate additional evidence on whether the innovation can achieve social impact and market viability, for commercial innovations.
Scale – the innovation has a strong evidence base and logistically credible plan for scaling to reach millions of people. Funding of up to USD 15 million is available to expand the reach of innovations with a view to reaching millions of people in the long term if successful.
What they Fund?
At GIF, they believe that innovation, by which they mean any solution that has potential to address an important development problem more effectively than existing approaches, can come from anyone, anywhere.
This means that they accept applications working in any sector in any developing country.
Any type of organisation may apply. This includes social enterprises, for-profit companies, non-profit organisations, government agencies, international organisations, and research institutions in any country. It is recommended that individual innovators, entrepreneurs, or researchers apply through an affiliated organisation.
Any type of organisation may apply. This includes social enterprises, for-profit companies, non-profit organisations, government agencies, international organisations, and research institutions in any country. It is recommended that individual innovators, entrepreneurs or researchers apply through an affiliated organisation.
GIF is open to innovations which meet their criteria in any sector or country. However, there are some activities they do not fund. These include:
You can sign up below to receive the EpiCARE Research Calls Newsletters, sent a few times a year, to inform about the new research calls: